Log in or Sign up for Free to view tailored content for your specialty!
Juvenile Arthritis News
EULAR: Systemic JIA, adult-onset Still’s disease ‘are the same disease’
Systemic juvenile idiopathic arthritis and adult-onset Still’s disease have been combined into one entity called Still’s disease in new recommendations document presented at the EULAR 2023 Congress.
Coherus to launch adalimumab biosimilar in US at 85% discount
Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.
Log in or Sign up for Free to view tailored content for your specialty!
Lower family income predicts longer hospital stays in children with lupus
Family income level is a significant predictor of longer hospital stays among children with lupus in the lowest income quartile, according to data published in Arthritis Care & Research.
FDA approves ‘high-concentration, citrate-free’ Yuflyma as ninth Humira biosimilar
The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.
FDA approves autoinjector option for upcoming adalimumab biosimilar
The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.
TMJ involvement, dentofacial deformity ‘frequent complications’ of juvenile arthritis
Approximately 30% of patients with juvenile idiopathic arthritis develop temporomandibular joint involvement before transitioning to adult care, according to data published in Arthritis & Rheumatology.
Female sex, ANA positivity predict higher risk for autoimmune thyroid disease in JIA
Patients with juvenile idiopathic arthritis who demonstrate female sex, antinuclear antibody positivity and a positive family history have a higher risk for autoimmune thyroid disease, according to data published in Pediatric Rheumatology.
FDA approves citrate-free, high-concentration form of biosimilar Hyrimoz
The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.
MIS-C outcomes with glucocorticoids alone similar to IVIG, combination therapy
Glucocorticoids alone demonstrate similar recovery rates as intravenous immunoglobin, or combination therapy with both, in patients with multisystem inflammatory syndrome in children, according to data published in The Lancet Rheumatology.
EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis
Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.
-
Headline News
WikiGuidelines group publishes first new UTI guidance in 14 years
November 11, 20243 min read -
Headline News
Q&A: Industrial fires present unique respiratory health risks
November 11, 20244 min read -
Headline News
Physicians encouraged to conduct oral food challenges for infants, toddlers
November 12, 20247 min read
-
Headline News
WikiGuidelines group publishes first new UTI guidance in 14 years
November 11, 20243 min read -
Headline News
Q&A: Industrial fires present unique respiratory health risks
November 11, 20244 min read -
Headline News
Physicians encouraged to conduct oral food challenges for infants, toddlers
November 12, 20247 min read